Drug Research
Eisai to market and distribute Belviq weight management therapy in US
Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity. Indicated for people with...
Drug Research
Johnson & Johnson opens California Innovation Center
Johnson & Johnson (J&J) Innovation has opened the new California Innovation Center to build early stage collaborations with emerging companies in science and technology and advance healthcare. The new centre has the flexibility to adapt...
Drug Research
Second Genome signs microbiome drug discovery deal with Janssen
Second Genome has signed a microbiome drug discovery deal with Janssen Biotech to advance novel drug targets mediated by the bacterial ecosystem living within the human gut to treat ulcerative colitis. Under the collaboration, Janssen...
Drug Research
USPTO issues notice of allowance for GW Pharmaceuticals Sativex formulation spray device
The USPTO has issued a notice of allowance for GW Pharmaceuticals' patent application regarding Sativex formulation spray device. The patent alleges a metered valve pump spray device comprising a liquid cannabis extract, in propylene...
Drug Research
Nuvo Research announces launch of Pliaglis in Europe
Specialty pharmaceutical company Nuvo Research has announced the launch of Pliaglis (lidocaine and tetracaine) cream 7%/7% by Galderma in Europe. Galderma has worldwide marketing rights for Nuvo's Pliaglis, a topical local anesthetic cream indicated...
Drug Research
UK, India sign deal to support R&D, innovation projects
The Technology Strategy Board (TSB) in the UK and the Indian government's Department of Science and Technology have signed 'Programme of Co-operation' deal to support joint, collaborative research and development (R&D) and innovation projects in key areas, including...
Drug Research
ImmBio gets Biomedical Catalyst support to develop pneumococcal vaccine PnuBioVax
Immunobiology (ImmBio), a UK-based biopharmaceutical company, has bagged £0.2m in funding from the UK government-backed Biomedical Catalyst (BBC) for the pre-clinical development of pneumococcal vaccine PnuBioVax. The pharma company had also received £1m from...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
